Prezista (darunavir) / J&J 
Welcome,         Profile    Billing    Logout  
 32 Diseases   11 Trials   11 Trials   1696 News 


12345678910111213...2021»
  • ||||||||||  Journal:  Emerging integrase resistance in an international perinatal virtual clinic. (Pubmed Central) -  Jan 29, 2025   
    Our results did not show viremia to be predictive of CVD among people with HIV. Although uncommon, INSTI resistance is emerging, mainly in highly treatment experienced CAWHIV from LMIC, highlighting the global need for access to boosted protease inhibitors and novel classes, including formulations for children less than 35?kg.
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion:  Body Composition Sub-study of the D2EFT Trial (clinicaltrials.gov) -  Jan 9, 2025   
    P4,  N=155, Completed, 
    The work lays the foundation for potential therapeutic interventions in treating COVID-19. Active, not recruiting --> Completed
  • ||||||||||  Prezista (darunavir) / J&J
    FDA event, Journal:  Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach. (Pubmed Central) -  Dec 6, 2024   
    In silico results suggest that Atazanavir is a promising candidate for targeting SARS-CoV-2 Mpro, with strong binding affinity and dynamic stability. These findings support its potential as a lead compound for further preclinical and clinical testing, though in vitro and in vivo validation are needed to confirm its therapeutic efficacy against COVID-19.
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Biomarker, Journal:  Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study. (Pubmed Central) -  Nov 3, 2024   
    A relevant proportion of neurologically asymptomatic participants had abnormal CSF and serum NFL levels during primary HIV infection. NFL and GFAP decreased in serum following combination antiretroviral therapy without significant differences among the treatment arms.
  • ||||||||||  Prezista (darunavir) / J&J
    Journal:  Design, Synthesis, and Biological Evaluation of Darunavir Analogs as HIV-1 Protease Inhibitors. (Pubmed Central) -  Oct 21, 2024   
    Further structural dynamics and energetic analyses confirmed the stability and binding affinity of promising analogs, particularly 5ae, which showed strong interactions with key residues in HIV-1 PR. Overall, this study underscores the importance of flexible moieties and interaction enhancement at the S2' subsite of HIV-1 PR in developing effective DRV analogs to combat HIV and other global health issues.
  • ||||||||||  Selzentry (maraviroc) / ViiV Healthcare
    Phase classification:  Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen (clinicaltrials.gov) -  Oct 15, 2024   
    P2,  N=262, Completed, 
    Overall, this study underscores the importance of flexible moieties and interaction enhancement at the S2' subsite of HIV-1 PR in developing effective DRV analogs to combat HIV and other global health issues. Phase classification: P2b --> P2
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
    HERV-K/HML-2 suppression using antiretroviral therapy in ALS (517d) -  Oct 1, 2024 - Abstract #ALSMND2024ALS_MND_44;    
    P1
    There was a rebound in HERV-K/HML-2 levels after ART discontinuation, further supporting target engagement. Compared to non-responders, the responders had a slower rate of decrease in the ALSFRSR at 24 weeks.
  • ||||||||||  Prezista (darunavir) / J&J, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
    Challenges in Managing Hepatitis B Reactivation in an HIV-Positive Patient on Dialysis for End-Stage Renal Disease (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_3629;    
    This evidence should be carefully considered in clinical conditions requiring higher dolutegravir exposure, such as in the presence of drug-drug interactions with drugs known to reduce dolutegravir bioavailability or in highly experienced PWH. Patient was started on emtricitabine/tenofovir alafenamide (Descovy)...Current regimen includes Prezista, ritonavir, TDF, dolutegravir, and lamivudine...Treatment should continue for at least 6 months after discontinuation of immunosuppressive medications
  • ||||||||||  Prezista (darunavir) / J&J
    Journal:  Opsonization-independent antigen-specific recognition by myeloid phagocytes expressing monoclonal antibodies. (Pubmed Central) -  Aug 10, 2024   
    A first cloned B-VIREM-derived antibody (Vab1) specifically binds stomatin, a ubiquitous scaffold protein that is strictly expressed intracellularly, allowing Vab1-bearing macrophages to phagocytose cell debris without requiring prior opsonization. Our results suggest important antigen-specific tissue maintenance functionalities in these innate immune cells.
  • ||||||||||  Prezista (darunavir) / J&J, Edurant (rilpivirine) / J&J, Dovato (dolutegravir/lamivudine) / ViiV Healthcare
    Is the U=U status maintained after switching to a dual regimen? The answer from the Icona cohort Study (Limatambo 2/Channel 2) -  Aug 9, 2024 - Abstract #HIVR4P2024HIVR4P_61;    
    We included PWH in the ICONA cohort who had reached a U=U status as of January 2014 while on triple therapy and were subsequently switched to dolutegravir(DTG)+lamivudine(3TC), DTG+rilpivirine(RPV) or darunavir/boosted(DRV/b)+3TC therapy. Our findings confirm a low risk of losing U=U after switching to 2DR, regardless of the type of therapy used.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Dolutegravir Resistance in African Programmatic Settings Among Patients With Failure of Dolutegravir-based ART. (Pubmed Central) -  Jul 1, 2024   
    Prospective research is needed to understand the scope of the problem, identify additional risk factors, and determine best management. In the short term, for most patients with dolutegravir resistance and prior non-nucleoside reverse transcriptase inhibitor exposure, the best option will be a timely switch to a regimen anchored by a boosted protease inhibitor, with a high genetic barrier to resistance.
  • ||||||||||  CoAprovel (irbesartan hydrochlorothiazide) / Sanofi, Prezista (darunavir) / J&J
    Journal:  Comparing the adsorption of micropollutants on activated carbon from anaerobically stored, organics-depleted, and nitrified urine. (Pubmed Central) -  May 27, 2024   
    In addition, we showed that the relative pharmaceutical removal in all solutions was independent of the initial pharmaceutical concentration unless the background organics matrix changed considerably. We conclude that removal of micropollutants in GAC columns from organics-depleted urine can be performed without clogging, but with the drawback of a higher carbon usage compared to removal from nitrified urine.
  • ||||||||||  Prezista (darunavir) / J&J, Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    FDA event, Review, Journal:  Pathogenesis of COVID19 and the applications of US FDA-approved repurposed antiviral drugs to combat SARS-CoV-2 in Saudi Arabia: A recent update by review of literature. (Pubmed Central) -  May 27, 2024   
    In this article, several COVID19-related discussions have been provided including emerging variants of concern of, COVID19 pathogenesis, COVID19 pandemic scenario in Saudi Arabia, drug repurposing strategies against SCV-2, as well as repurposing of US FDA-approved antiviral drugs that might be considered to combat SCV-2 in Saudi Arabia. Moreover, drug repurposing in the context of COVID19 management along with its limitations and future perspectives have been summarized.
  • ||||||||||  Prezista (darunavir) / J&J, Intelence (etravirine) / J&J
    SAT062 Treatment failure management in children - New Horizons Advancing Pediatric Care Collaborative (Room 13a/Channel 6) -  May 2, 2024 - Abstract #AIDS2024AIDS_530;    
    As 2024 is the 10th anniversary of NH, J&J and EGPAF want to celebrate and publicize the successes, lessons learned and tools developed through the collaborative. The satellite session will feature high-level speakers from J&J, EGPAF and other pediatric HIV stakeholders to highlight the need for a focus on treatment failure management in children and show data and success stories from NH that addresses these gaps.
  • ||||||||||  Detailed modelling of viremia exposure does not independently predict cardiovascular disease in people with HIV (Hall B0b/Channel 5) -  May 2, 2024 - Abstract #AIDS2024AIDS_422;    
    The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Tuesday, 23 July 2024, at 10:00 am Central European Summer Time (CEST). If an abstract is part of an official AIDS 2024 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference.
  • ||||||||||  Prezista (darunavir) / J&J, Edurant (rilpivirine) / J&J, Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo
    Review, Journal:  Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas. (Pubmed Central) -  Apr 27, 2024   
    For those intolerant or not meeting therapeutic goals, the addition of ezetimibe, PCSK9, bempedoic acid, fibrates, or fish oils should also be considered. This review summarizes the current literature on the multifactorial etiology and intricate pathophysiology of hyperlipidemia in PLHIV, with an emphasis on the role of different HAART agents, while also providing valuable insights into potential switching strategies and therapeutic options.
  • ||||||||||  Prezista (darunavir) / J&J, Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
    Journal:  Exploring Darunavir, Rilpivirine and Etravirine as Potential Therapies for Bladder Cancer: Efficacy and Synergistic Effects. (Pubmed Central) -  Mar 28, 2024   
    In summary, this pre-clinical investigation underscores the promising therapeutic potential of ETV and RPV, both as standalone treatments and in combination, hinting at repurposing opportunities in bladder cancer therapy, which could give a new treatment method for this disease that is faster and without as severe side effects as anticancer drugs. These findings represent a substantial stride in advancing personalized medicine within cancer research and will be further scrutinized in forthcoming studies.
  • ||||||||||  dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Viatris, Hetero, Macleods
    Virologic Outcomes With Tenofovir-Lamivudine-Dolutegravir for PI-Based Second-Line ART Failure () -  Mar 16, 2024 - Abstract #CROI2024CROI_903;    
    These findings represent a substantial stride in advancing personalized medicine within cancer research and will be further scrutinized in forthcoming studies. Background: Patients failing protease inhibitor (PI)-based 2nd-line antiretroviral therapy (ART) in the South African ART programme qualify for genotypic antiretroviral resistance testing (GART)
  • ||||||||||  First Trimester Exposure to Newer Antiretroviral Agents and Congenital Anomalies in a US Cohort (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_769;    
    The odds of congenital anomalies among infants with first trimester exposure to newer ARVs did not differ substantially from that among infants unexposed to these specific ARVs. However, modest effects cannot be ruled out, highlighting the need for continued evaluation of these associations in larger populations.
  • ||||||||||  Difficult-to-Treat HIV in Sweden: Describing the Current Landscape (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_694;    
    Although 9% of the HIV cohort in Sweden in 2023 were classified as having difficult-to-treat HIV, a large proportion of these were virally suppressed. Challenges such as advanced resistance and need for salvage therapy are rare in the current Swedish cohort.
  • ||||||||||  Estimated Costs of Eliminating Medicaid Prior Authorizations for Antiretrovirals in Washington State (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_544;    
    PrEP models assumed a 10% annual increase in the number of PrEP users and evaluated the impact of annual declines in the relative percentage of PrEP users on TDF/FTC with compensatory increases in TAF/FTC use; some models assumed the percentage of PrEP users on cabotegravir (CAB) would increase 1% annually...Our No PA Model assumed: 1) 18% annual relative increase in the percentage of PLWH on bictegravir/TAF/FTC; 2) the percentage of people on tenofovir/FTC taking TAF/FTC (vs. TDF/FTC) increases 9% annually; 3) CAB/rilpivirine increases 1% annually; 4) no change in darunavir/cobisistat; and 5) use of other ART drugs decline in proportion to their 2022 use...Elimination of Medicaid PAs will likely result in substantial new costs. Changes in drug formulary policy should consider opportunity costs.